TY - JOUR
T1 - Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
AU - Perez-Fidalgo, Alejandro
AU - Schmalfeldt, Barbara
AU - George, Angela
AU - Gourley, Charlie
AU - Pignata, Sandro
AU - Lorusso, Domenica
AU - Barretina-Ginesta, Maria Pilar
AU - Romero, Ignacio
AU - Grimm, Christoph
AU - Van Gorp, Toon
AU - Rossing, Maria
AU - Collins, Dearbhaile C.
AU - Fernebro, Josefin
AU - Bjorge, Line
AU - Leary, Alexandra
AU - De La Motte Rouge, Thibault
AU - Harter, Philipp
AU - Kurzeder, Christian
AU - Savva-Bordalo, Joana
AU - You, Benoit
N1 - Publisher Copyright:
© IGCS and ESGO 2024. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Objectives: Maintenance therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors and/or bevacizumab, have substantially improved the prognosis of patients with advanced ovarian cancer. Owing to the variability in treatment strategies across Europe, a Delphi study was conducted among European experts to understand the heterogeneity of clinical practice and identify key factors driving maintenance treatment decisions for advanced ovarian cancer. Methods: A pragmatic literature review was conducted to identify key questions regarding maintenance treatment strategies in patients with advanced ovarian cancer. Utilizing a Delphi methodology, consensus was assessed among a panel of 16 experts using a questionnaire based on results of the pragmatic literature review. Results: Panelists agreed that BRCA mutation and homologous recombination status should be assessed in parallel at diagnosis, and that first-line platinum chemotherapy may be initiated concurrently. There was a consensus that alternative homologous recombination deficiency tests are acceptable provided they are clinically validated. Panelists agreed that Response Evaluation Criteria in Solid Tumors (RECIST) and CA-125 elimination rate constant K (KELIM) scores can help assess tumor chemosensitivity and guide treatment-related decisions. Panelists defined high-risk disease as International Federation of Gynecology and Obstetrics (FIGO) stage IV disease or stage III with residual disease after initial/interval cytoreduction. Risk of disease progression was a key determinant of choice between PARP inhibitor, bevacizumab, or both in combination, as maintenance therapy in advanced ovarian cancer. Conclusions: Key drivers for selecting advanced ovarian cancer maintenance treatments include tumor mutational status as a key biomarker and clinician perception of the risk for early disease progression.
AB - Objectives: Maintenance therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors and/or bevacizumab, have substantially improved the prognosis of patients with advanced ovarian cancer. Owing to the variability in treatment strategies across Europe, a Delphi study was conducted among European experts to understand the heterogeneity of clinical practice and identify key factors driving maintenance treatment decisions for advanced ovarian cancer. Methods: A pragmatic literature review was conducted to identify key questions regarding maintenance treatment strategies in patients with advanced ovarian cancer. Utilizing a Delphi methodology, consensus was assessed among a panel of 16 experts using a questionnaire based on results of the pragmatic literature review. Results: Panelists agreed that BRCA mutation and homologous recombination status should be assessed in parallel at diagnosis, and that first-line platinum chemotherapy may be initiated concurrently. There was a consensus that alternative homologous recombination deficiency tests are acceptable provided they are clinically validated. Panelists agreed that Response Evaluation Criteria in Solid Tumors (RECIST) and CA-125 elimination rate constant K (KELIM) scores can help assess tumor chemosensitivity and guide treatment-related decisions. Panelists defined high-risk disease as International Federation of Gynecology and Obstetrics (FIGO) stage IV disease or stage III with residual disease after initial/interval cytoreduction. Risk of disease progression was a key determinant of choice between PARP inhibitor, bevacizumab, or both in combination, as maintenance therapy in advanced ovarian cancer. Conclusions: Key drivers for selecting advanced ovarian cancer maintenance treatments include tumor mutational status as a key biomarker and clinician perception of the risk for early disease progression.
KW - Ovarian Cancer
UR - http://www.scopus.com/inward/record.url?scp=85214644274&partnerID=8YFLogxK
U2 - 10.1136/ijgc-2024-005497
DO - 10.1136/ijgc-2024-005497
M3 - Article
C2 - 39448084
AN - SCOPUS:85214644274
SN - 1048-891X
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
M1 - 1 10
ER -